BioCentury | Nov 15, 2016
Distillery Therapeutics

Cancer

...FOXD1 or ALDH1A3 was associated with poor survival. In human gliomal cell lines, shRNA targeting FOXD1...
...of glioma, FOXD1 knockdown in tumors decreased tumor growth and increased survival compared with normal FOXD1...
...survival compared with no treatment. Next steps could include identifying and testing FOXD1 inhibitors. TARGET/MARKER/PATHWAY: Forkhead box D1 (FOXD1)...
Items per page:
1 - 1 of 1